Article Details
Retrieved on: 2025-05-14 15:38:27
Tags for this article:
Click the tags to see associated articles and topics
Excerpt
Tony Wood, Chief Scientific Officer, GSK said: “The FGF21 class has shown some of the most exciting data in MASH including first-in-disease evidence ...
Article found on: www.gsk.com
This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here